Showing 161 - 180 results of 60,039 for search '(((( a step decrease ) OR ( 2 we decrease ))) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 0.74s Refine Results
  1. 161
  2. 162

    Image1_Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.TIF by Franciel Batista Felix (10699536)

    Published 2021
    “…BCA treatment shortened Ri from ∼23 h observed in vehicle-treated mice to ∼5.5 h, associated with an increase in apoptotic events and efferocytosis, both key steps for the resolution of inflammation. These effects of BCA were prevented by H89, an inhibitor of protein kinase A (PKA) and G15, a selective G protein–coupled receptor 30 (GPR30) antagonist. …”
  3. 163

    Image4_Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.TIF by Franciel Batista Felix (10699536)

    Published 2021
    “…BCA treatment shortened Ri from ∼23 h observed in vehicle-treated mice to ∼5.5 h, associated with an increase in apoptotic events and efferocytosis, both key steps for the resolution of inflammation. These effects of BCA were prevented by H89, an inhibitor of protein kinase A (PKA) and G15, a selective G protein–coupled receptor 30 (GPR30) antagonist. …”
  4. 164

    Image3_Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.TIF by Franciel Batista Felix (10699536)

    Published 2021
    “…BCA treatment shortened Ri from ∼23 h observed in vehicle-treated mice to ∼5.5 h, associated with an increase in apoptotic events and efferocytosis, both key steps for the resolution of inflammation. These effects of BCA were prevented by H89, an inhibitor of protein kinase A (PKA) and G15, a selective G protein–coupled receptor 30 (GPR30) antagonist. …”
  5. 165
  6. 166
  7. 167

    Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

    Published 2023
    “…</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …”
  8. 168

    Table1_Loss-of-function N178T variant of the human P2Y4 receptor is associated with decreased severity of coronary artery disease and improved glucose homeostasis.DOCX by Michael Horckmans (14206388)

    Published 2022
    “…The relevance of these data has, however, not been explored to date in humans. In a population study comprising 50 patients with coronary artery disease (CAD) and 50 age-matched control individuals, we analyzed P2RY4 mutations and their potential association with CAD severity and fasting plasma parameters. …”
  9. 169

    Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

    Published 2020
    “…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175

    Elementary Steps in Olefin Metathesis: Nickelacyclobutanes via Cycloaddition to Nickel Carbenes by Samantha K. Cormier (16872384)

    Published 2025
    “…We describe Ni(PP)(=CPh<sub>2</sub>) complexes that provide this missing evidence. …”
  16. 176

    Palmitic acid decreases cell migration by increasing RGS2 expression and decreasing SERCA expression by Octavio Galindo-Hernandez (10350992)

    Published 2021
    “…Also, overexpression of individual proteins, RGS2 and SERCA, produced a decrease and an increase on cell migration, respectively. …”
  17. 177
  18. 178

    S2 File - by Yosuke Kameno (342665)

    Published 2023
    “…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”
  19. 179
  20. 180